{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:35:04Z","timestamp":1790112904265,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005699","name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogadro","doi-asserted-by":"publisher","award":["JP21nf010626"],"award-info":[{"award-number":["JP21nf010626"]}],"id":[{"id":"10.13039\/501100005699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017570","name":"Tokyo Shinagawa Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.06.032","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T21:17:47Z","timestamp":1655759867000},"page":"4328-4333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2\/3, randomized, observer-blinded, noninferiority study"],"prefix":"10.1016","volume":"40","author":[{"given":"Masaharu","family":"Shinkai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa Yokokawa","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi M.","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.06.032_b0005","doi-asserted-by":"crossref","unstructured":"Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021;385:e84. <https:\/\/doi.org\/10.1056\/nejmoa2114583>.","DOI":"10.1056\/NEJMoa2114583"},{"issue":"10309","key":"10.1016\/j.vaccine.2022.06.032_b0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.032_b0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.032_b0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.06.032_b0025","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.4008873","article-title":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: a report of interim findings","author":"Iwata","year":"2022","journal-title":"SSRN Electron J [Internet]"},{"key":"10.1016\/j.vaccine.2022.06.032_b0030","unstructured":"Office of Vaccines and Blood Products, Pharmaceuticals and Medical Device Agency, Japan. Principles for the evaluation of vaccines against the novel coronavirus SARS-CoV-2 (Appendix 3); 2021. <https:\/\/www.pmda.go.jp\/files\/000243339.pdf> [accessed 25 February 2022]."},{"issue":"17","key":"10.1016\/j.vaccine.2022.06.032_b0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.032_b0040","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"issue":"10304","key":"10.1016\/j.vaccine.2022.06.032_b0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","article-title":"Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)","volume":"398","author":"Flaxman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.06.032_b0050","doi-asserted-by":"crossref","unstructured":"Mallory R, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. MedRxiv 2021:2021.12.23.21267374. <https:\/\/doi.org\/10.1101\/2021.12.23.21267374>.","DOI":"10.1101\/2021.12.23.21267374"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.032_b0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-021-00596-5","article-title":"Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine","volume":"32","author":"Cao","year":"2022","journal-title":"Cell Res"},{"issue":"10318","key":"10.1016\/j.vaccine.2022.06.032_b0060","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.032_b0065","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"10316","key":"10.1016\/j.vaccine.2022.06.032_b0070","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"6581","key":"10.1016\/j.vaccine.2022.06.032_b0075","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine\u2013elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.032_b0080","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"issue":"590","key":"10.1016\/j.vaccine.2022.06.032_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf7517","article-title":"T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals","volume":"13","author":"Bilich","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2022.06.032_b0090","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.032_b0095","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:13:53Z","timestamp":1759403633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":19,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22007812"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.032","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.03.22271827","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2\/3, randomized, observer-blinded, noninferiority study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}